Cisplatin resistance: preclinical findings and clinical implications

Biochimica Et Biophysica Acta
B KöberleBernd Kaina

Abstract

Cisplatin is used for the treatment of many types of solid cancers. While testicular cancers respond remarkably well to cisplatin, the therapeutic efficacy of cisplatin for other solid cancers is limited because of intrinsic or acquired drug resistance. Our understanding about the mechanisms underlying cisplatin resistance has largely arisen from studies carried out with cancer cell lines in vitro. The process of cisplatin resistance appears to be multifactorial and includes changes in drug transport leading to decreased drug accumulation, increased drug detoxification, changes in DNA repair and damage bypass and/or alterations in the apoptotic cell death pathways. Translation of these preclinical findings to the clinic is emerging, but still scarce. The present review describes and discusses the clinical relevance of in vitro models by comparing the preclinical findings to data obtained in clinical studies.

References

Oct 7, 1992·Journal of the National Cancer Institute·M DabholkarE Reed
May 1, 1991·British Journal of Cancer·D MurphyB W Fox
Aug 2, 1984·Nature·A WesterveldD Bootsma
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G van der ZeeE G de Vries
Nov 1, 1994·International Journal of Cancer. Journal International Du Cancer·S L JonesP R Harnett
Jun 7, 1994·Proceedings of the National Academy of Sciences of the United States of America·D K TreiberJ M Essigmann
Jun 25, 1996·Proceedings of the National Academy of Sciences of the United States of America·D R DuckettP Modrich
Mar 4, 1997·International Journal of Cancer. Journal International Du Cancer·B KöberleJ R Masters
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·J YanevaJ Zlatanova
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R MetzgerL Leichman
Aug 29, 1998·The Journal of Biological Chemistry·Q LiE Reed
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D Lebwohl, R Canetta
Jan 5, 2000·The Journal of Investigative Dermatology·T M RüngerD Hellfritsch
Mar 10, 2000·International Journal of Cancer. Journal International Du Cancer·C MeijerN H Mulder
Jul 7, 2000·The Journal of Biological Chemistry·I KuraokaR D Wood
Sep 23, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J HolfordL R Kelland
Oct 12, 2000·Cellular and Molecular Life Sciences : CMLS·P Jordan, M Carmo-Fonseca
Feb 15, 2001·Nature Cell Biology·P ListonR G Korneluk
Mar 10, 2001·International Journal of Cancer. Journal International Du Cancer·J KatoY Fujii

❮ Previous
Next ❯

Citations

Oct 1, 2013·Expert Reviews in Molecular Medicine·R KosterS de Jong
Mar 6, 2012·Molecular Pharmacology·Shilpy SharmaChristine E Canman
May 18, 2011·Molecular Cancer·Matthias PortMichael Abend
Apr 22, 2011·Journal of Hematology & Oncology·Xiaoxin S XuGan Wang
Dec 14, 2011·PloS One·Eva M Galan-MoyaRicardo Sánchez-Prieto
May 15, 2013·PloS One·Yu-Liang WangXiang-Dong Zhou
May 31, 2014·Cell Death & Disease·L GalluzziG Kroemer
May 23, 2014·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Marilù SinisiGiovanni Natile
Jul 27, 2014·European Journal of Medicinal Chemistry·Joan AlbertMarta Cascante
Sep 23, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Pieter SpincemailleKarin Thevissen
Sep 4, 2015·Expert Opinion on Drug Delivery·Tinghe YuLi Wang
Jul 19, 2013·Toxicology Mechanisms and Methods·Iwona JarockaElżbieta Skrzydlewska
Oct 16, 2013·Advances in Medical Sciences·A GęgotekE Skrzydlewska
Apr 27, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Peng KuangYinmin Zhao
Apr 26, 2012·International Journal of Pharmaceutics·Lin WuYiqiao Hu
Jan 31, 2012·Biochemical Pharmacology·Maria E Palm-Espling, Pernilla Wittung-Stafshede
Mar 2, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Wantong SongXuesi Chen
Nov 7, 2015·Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology·Ewelina GuszpitRene Kizek
Oct 16, 2015·Dalton Transactions : an International Journal of Inorganic Chemistry·J R BerenguerS Piñeiro-Hermida
Jan 23, 2013·Cell Biology International·Vildan Bozok CetintasZuhal Eroglu
May 15, 2015·ChemistryOpen·Chiara NardonDolores Fregona
Dec 19, 2015·Oxidative Medicine and Cellular Longevity·Stéphanie Anaís CastaldoPatrícia Alexandra Madureira
Nov 15, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xiao HeXiefu Zhang
Aug 19, 2015·Mutation Research. Reviews in Mutation Research·Adam D ThomasBernd Kaina
Jun 6, 2015·European Journal of Medicinal Chemistry·Bin-Bin LiPak-Hing Leung
Aug 27, 2013·The International Journal of Biochemistry & Cell Biology·Lu LuXuejun Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Critical Reviews in Oncology/hematology
David Stewart
Nature Reviews. Drug Discovery
Dong Wang, Stephen J Lippard
Dalton Transactions : an International Journal of Inorganic Chemistry
Nial J WheateRabbab Oun
© 2021 Meta ULC. All rights reserved